Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Part I 1. Objective: Evaluate the safety and tolerability of MK-1439, at the studied doses, compared to efavirenz, each in combination with TRUVADA® for 24 weeks. 2. Objective: Evaluate the antiretroviral activity of MK-1439, at the studied doses, compared to efavirenz, each in combination with TRUVADA® for 24 weeks, as measured by the proportion of patients with HIV RNA <40 copies/mL at Week 24. Part I and Part II Combined 1. Objective: Evaluate the safety and tolerability of MK-1439, at the final selected dose, compared to efavirenz, each in combination with TRUVADA® for 24 weeks. 2. Objective: Evaluate the central nervous system adverse events (CNS events) associated with the use of the final selected dose of MK-1439 compared with efavirenz, each in combination with TRUVADA® as measured by the proportion of patients with CNS events by Week 8 and by Week 24. Parte I. 1. Objetivo: Evaluar la seguridad y la tolerabilidad de MK-1439, en las dosis estudiadas, comparado con efavirenz, siempre en asociación con TRUVADA®, durante 24 semanas. 2. Objetivo: Evaluar la actividad antirretroviral de MK-1439, en las dosis estudiadas, comparado con efavirenz, siempre en asociación con TRUVADA®, durante 24 semanas, a juzgar por el porcentaje de pacientes con ARN del VIH < 40 copias/ml en la semana 24.
Critère d'inclusion
- Human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral naïve HIV-infected patients,Virus de la inmunodeficiencia humana de tipo 1 (VIH-1), en pacientes infectados por el VIH, sin tratamiento antirretroviral previo